Therapeutic Response

ER positive and HER2-negative status confers therapeutic sensitivity to Everolimus in combination with Exemestane in patients with Invasive Breast Carcinoma.

Statements

Source and description
Afinitor (everolimus) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.
Afinitor (everolimus) [product monograph]. HC. Health Canada approved everolimus in combination with exemestane for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer after recurrence or progression following treatment with letrozole or anastrozole.